Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

U.S. to invest another $1 bln in rapid COVID-19 tests

10/06/2021 | 03:53pm EST

Oct 6 (Reuters) - The U.S. government is committing to purchase an additional 180 million rapid COVID-19 tests for $1 billion, adding to the $2 billion test buying plan it announced in September, a top U.S. health official said on Wednesday.

The combined purchases will help quadruple the United States' test output by December to around 200 million tests per month, Jeff Zients, the White House coronavirus response coordinator, said during a press call.

"We'll continue to pull every lever to expand manufacturing production of tests which will have the impact of driving down the cost per test and making sure that tests are widely available and convenient," Zients said.

The government will also double the number of pharmacies it partners with to provide free COVID-19 tests to 20,000 pharmacies, Zients added.

Surging demand for COVID-19 tests from U.S. employers has exacerbated a nationwide shortage of rapid tests in recent weeks and is driving up costs for state and local testing programs.

The White House in September said it plans to mandate weekly testing for unvaccinated staff at businesses with more than 100 employees.

The U.S. government agreed in September to purchase $2 billion worth of rapid COVID-19 tests from Abbott Laboratories and Celltrion Inc to ship to nursing homes and other high risk populations as part of President Joe Biden's plans to increase vaccinations and tests.

The U.S. government also has agreements to purchase tests from other manufacturers, including Quidel Corp., OraSure Technologies, and Intrivo.

Earlier this week, U.S. regulators authorized another rapid test from Acon Technologies that can be taken at home. Zients said the test will retail for around $10 per test.

The average number of daily U.S. coronavirus cases dropped by 12% over the last seven days to nearly 98,000, and hospitalizations dropped 14% to 7,400, said U.S. Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky said during the briefing.

She cautioned that deaths remained constant at 1,400 per day.

(Reporting by Carl O'Donnell; Editing by Leslie Adler and Aurora Ellis)

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELLTRION, INC. -1.17% 210500 End-of-day quote.-41.36%
ORASURE TECHNOLOGIES, INC. -2.68% 8.7 Delayed Quote.-17.81%
QUIDEL CORPORATION 0.99% 147.95 Delayed Quote.-17.65%
All news about CELLTRION, INC.
12/02U.S. OMICRON PLAN : boosters, free at-home tests, tighter travel rules
11/29Celltrion signs COVID-19 antibody therapy supply deals with Europe
11/15Celltrion Receives CHMP Positive Opinion for regdanvimab (CT-P59) as One of the First M..
11/15Celltrion Inc. Shares Rally After EU Approves Marketing of Its Covid-19 Treatment
11/15European Commission Approves Celltrion's Antibody COVID-19 Treatment
11/15Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
11/15S.Korea stocks end 1% higher on chip, biopharma boost, U.S. data in focus
11/15S&P Upgrades ITV To Stable From Negative On Expected Revenue Recovery
11/12EC Formally Authorises COVID-19 Drugs From Regeneron-Roche, Celltrion
11/11EU Drug Regulator Backs COVID-19 Therapy from South Korea's Celltrion
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sales 2021 1 904 B 1,61 B 1,61 B
Net income 2021 586 B 0,50 B 0,50 B
Net cash 2021 246 B 0,21 B 0,21 B
P/E ratio 2021 50,5x
Yield 2021 0,01%
Capitalization 28 759 B 24 298 M 24 359 M
EV / Sales 2021 15,0x
EV / Sales 2022 12,1x
Nbr of Employees 2 034
Free-Float 76,0%
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 210 500,00 KRW
Average target price 287 437,50 KRW
Spread / Average Target 36,5%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-41.36%24 298
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
SEAGEN INC.-13.93%27 564